Lactulose Fresenius Kabi (Lactulose, Liquid)

Lactulose is an osmotic laxative; it remains unabsorbed in the small intestine, drawing water into the colon to soften stool and increase transit. In the colon, bacterial fermentation produces short‑chain acids that lower pH, converting ammonia to ammonium and reducing its absorption.

The dose of lactulose is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber determines the appropriate volume and frequency, and adjustments are made as needed during therapy.

Safety data for lactulose in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lactulose differs from agents such as polyethylene glycol (PEG) in that it is metabolized by colonic bacteria to produce acids that also lower ammonia levels, making it useful for hepatic encephalopathy. PEG primarily acts as a pure osmotic agent without the ammonia‑lowering effect.

Store the liquid at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Ensure the bottle is tightly closed to maintain stability and prevent contamination.

The product is taken orally. The prescribed volume is measured with a calibrated device, such as a dosing cup or syringe, and can be swallowed directly or mixed with a small amount of water or juice to improve palatability.

Serious risks include severe dehydration, electrolyte imbalances such as hyponatremia, and rare allergic reactions that may present as rash, itching, or swelling. Patients should be monitored for these events, especially during high‑dose or prolonged therapy.

Lactulose is contraindicated in patients with galactosemia, complete intestinal obstruction, or severe inflammatory bowel disease where bowel motility is compromised. Caution is also advised for individuals with renal failure or uncontrolled electrolyte disorders.